Nektar Therapeutics (NKTR) News Today $1.38 +0.01 (+0.73%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 23 at 8:18 PM | msn.comB. Nektar Announces Their Latest ReleasesJuly 23 at 3:33 AM | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Hold" from AnalystsJuly 23 at 3:32 AM | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Consensus Recommendation of "Hold" by AnalystsNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and twJuly 18, 2024 | americanbankingnews.comNektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving Average of $1.08July 10, 2024 | marketbeat.comGSA Capital Partners LLP Lowers Stake in Nektar Therapeutics (NASDAQ:NKTR)GSA Capital Partners LLP reduced its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 62.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,989,905 shares of theJuly 6, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Stock Crosses Above 200-Day Moving Average of $1.02Nektar Therapeutics (NASDAQ:NKTR) Share Price Passes Above 200-Day Moving Average of $1.02June 28, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Receives New Coverage from Analysts at Rodman & RenshawRodman & Renshaw initiated coverage on shares of Nektar Therapeutics in a report on Friday. They issued a "buy" rating and a $2.00 price target for the company.June 22, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Share Price Crosses Above Two Hundred Day Moving Average of $0.98Nektar Therapeutics (NASDAQ:NKTR) Shares Cross Above 200-Day Moving Average of $0.98June 15, 2024 | insidertrades.comNektar Therapeutics (NASDAQ:NKTR) Director Sells $23,400.00 in StockJune 14, 2024 | marketbeat.comGSA Capital Partners LLP Has $2.97 Million Stake in Nektar Therapeutics (NASDAQ:NKTR)GSA Capital Partners LLP increased its stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 185.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 5,255,790 shares of the biopharmaceutical company's stock after acquiring anJune 12, 2024 | prnewswire.comNektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024May 30, 2024 | prnewswire.comNektar Management to Present at Upcoming Investor ConferencesMay 24, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)May 21, 2024 | insidertrades.comJonathan Zalevsky Sells 7,355 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockMay 21, 2024 | insidertrades.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells 16,650 Shares of StockMay 20, 2024 | marketbeat.comAssenagon Asset Management S.A. Cuts Stock Holdings in Nektar Therapeutics (NASDAQ:NKTR)Assenagon Asset Management S.A. reduced its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 31.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,687,300 shares of the biopharmaceMay 14, 2024 | insidertrades.comInsider Selling: Nektar Therapeutics (NASDAQ:NKTR) Major Shareholder Sells 56,000 Shares of StockMay 11, 2024 | marketbeat.comMonaco Asset Management SAM Buys 1,163,786 Shares of Nektar Therapeutics (NASDAQ:NKTR)Monaco Asset Management SAM grew its stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 24.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,973,387 shares of theMay 11, 2024 | uk.finance.yahoo.comQ1 2024 Nektar Therapeutics Earnings CallMay 11, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPSNektar Therapeutics (NASDAQ:NKTR - Get Free Report) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. The firm had revenue of $21.64 million for the quarter, compared to the consensus estimate of $14.91 million. Nektar Therapeutics had a negative net margin of 195.02% and a negative return on equity of 101.41%. During the same quarter in the previous year, the company earned ($0.25) earnings per share.May 10, 2024 | finance.yahoo.comNektar Therapeutics (NKTR) First Quarter 2024 Earnings OverviewMay 10, 2024 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call TranscriptMay 10, 2024 | msn.comNKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024May 9, 2024 | markets.businessinsider.comNektar Therapeutics Q1 Loss Drops In Line With EstimatesMay 9, 2024 | washingtonpost.comNektar: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comNektar Therapeutics Reports First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Nektar Therapeutics's earningsMay 3, 2024 | marketbeat.comNektar Therapeutics (NKTR) Scheduled to Post Quarterly Earnings on ThursdayNektar Therapeutics (NASDAQ:NKTR) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | prnewswire.comNektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsApril 24, 2024 | globenewswire.comBiolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune DiseasesApril 20, 2024 | finance.yahoo.comNatural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline DrugsApril 20, 2024 | investing.comNektar regains Nasdaq compliance with bid priceApril 10, 2024 | seekingalpha.comNektar Therapeutics Sees Something In The Data And Puts Its Drug To The TestApril 1, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Sees Large Growth in Short InterestNektar Therapeutics (NASDAQ:NKTR - Get Free Report) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 2,510,000 shares, a growth of 24.9% from the February 29th total of 2,010,000 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is presently 1.6 days.March 29, 2024 | yahoo.com“A fascinating listen that sometimes sounds like a missing 10cc album plus a little Be Box Deluxe”: Nektar’s Recycled 5CD setMarch 22, 2024 | prnewswire.comNektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 10, 2024 | marketbeat.comGSA Capital Partners LLP Increases Position in Nektar Therapeutics (NASDAQ:NKTR)GSA Capital Partners LLP lifted its position in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 931.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,841,078 shares of the biopharmaceutical company's stock after buying an additional 1,662March 7, 2024 | marketbeat.comWilliam Blair Equities Analysts Reduce Earnings Estimates for Nektar Therapeutics (NASDAQ:NKTR)Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Investment analysts at William Blair decreased their Q1 2024 earnings estimates for Nektar Therapeutics in a report issued on Tuesday, March 5th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will earn ($0.22) per sMarch 6, 2024 | marketbeat.comNektar Therapeutics to Post FY2026 Earnings of ($1.05) Per Share, William Blair Forecasts (NASDAQ:NKTR)Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Investment analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for Nektar Therapeutics in a report issued on Tuesday, March 5th. William Blair analyst A. Hsieh forecasts that the biopharmaceutical company will post earMarch 5, 2024 | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | marketbeat.comNektar Therapeutics' (NKTR) Market Perform Rating Reaffirmed at William BlairWilliam Blair reissued a "market perform" rating on shares of Nektar Therapeutics in a research report on Tuesday.March 5, 2024 | finance.yahoo.comQ4 2023 Nektar Therapeutics Earnings CallMarch 5, 2024 | prnewswire.comNektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataMarch 5, 2024 | marketbeat.comNektar Therapeutics (NASDAQ:NKTR) Given Average Rating of "Hold" by BrokeragesNektar Therapeutics (NASDAQ:NKTR - Get Free Report) has earned an average recommendation of "Hold" from the five ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation anMarch 4, 2024 | markets.businessinsider.comNektar Therapeutics Q4 Loss decreases, but misses estimatesMarch 4, 2024 | finance.yahoo.comNektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 ResultsMarch 4, 2024 | prnewswire.comNektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsMarch 4, 2024 | markets.businessinsider.comNektar Therapeutics Announces $30 Mln Private Placement Financing With TCGX; Stock Up In PremarketMarch 4, 2024 | prnewswire.comNektar Therapeutics Announces $30 Million Private Placement Financing with TCGXMarch 3, 2024 | markets.businessinsider.comNektar Therapeutics earnings: here's what Wall Street expects Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address How a $0.25 cent option contract makes my top traders feel (Ad)If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently… Click now to see for yourself what $0.25 Cent Trades is all about NKTR Media Mentions By Week NKTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKTR News Sentiment▼0.500.62▲Average Medical News Sentiment NKTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKTR Articles This Week▼52▲NKTR Articles Average Week Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADCT News Today AVIR News Today MCRB News Today PCRX News Today OMER News Today ASMB News Today CPIX News Today AGIO News Today ALKS News Today KRTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NKTR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
